Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.

Li, Nan

Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. [electronic resource] - Biomaterials Apr 2013 - 3366-80 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1878-5905

10.1016/j.biomaterials.2013.01.055 doi


Adenosine Triphosphate--metabolism
Animals
Antineoplastic Agents--pharmacology
Caspases--metabolism
Cell Death--drug effects
Cell Line, Tumor
Cell Survival--drug effects
Cytochromes c--metabolism
Drug Delivery Systems
Drug Resistance, Neoplasm--drug effects
Enzyme Activation--drug effects
Epirubicin--pharmacology
Female
Humans
Indazoles--pharmacology
Liposomes--chemistry
Membrane Potential, Mitochondrial--drug effects
Mice
Mice, Inbred BALB C
Mitochondria--drug effects
Myeloid Cell Leukemia Sequence 1 Protein
Neoplasms--drug therapy
Proto-Oncogene Proteins c-bcl-2--metabolism
Reactive Oxygen Species--metabolism
Signal Transduction--drug effects
Xenograft Model Antitumor Assays
bcl-2-Associated X Protein--metabolism